|
Competitive
Inhibition 96-Well Microtiter Plate ELISA Development
Quote
Introduction
In addition to the MoAb-PoAb
sandwich format, many immunoassays are structured in a
competitive inhibition format. Competitive
inhibition assays are often used to measure small
analytes because competitive inhibition assays only
require the binding of 1 antibody rather than 2 as is
used in standard ELISA formats. Because of the
high probability for steric hindrance occurring when 2
antibodies attempt to bind to a small molecule at the
same time, a sandwich
assay format may not be feasible, therefore a
competitive inhibition assay would be preferable.
In a sequential competitive inhibition assay, the sample
and conjugated analyte are added in steps like a
sandwich assay, while in a classic competitive
inhibition assay, these reagents are incubated together
at the same time.
In
a sequential competitive inhibition assay format, a
monoclonal antibody is coated onto a 96-well microtiter
plate. When the sample is added, the MoAb captures
free analyte out of the sample. In the next step, a
known amount of analyte labeled with either biotin or
HRP is added. The labeled analyte will then also
attempt to bind to the MoAb adsorbed onto the plate,
however, the labeled analyte is inhibited from binding
to the MoAb by the presence of previously bound analyte
from the sample. This means that the labeled analyte
will not be bound by the monoclonal on the plate if the
monoclonal has already bound unlabeled analyte from the
sample. The amount of unlabeled analyte in the sample is
inversely proportional to the signal generated by the
labeled analyte. The lower the signal, the more
unlabeled analyte there is in the sample. A
standard curve can be constructed using serial dilutions
of an unlabeled analyte standard. Subsequent
sample values can then be read off the standard curve as
is done in the sandwich ELISA formats.
The
classic competitive inhibition assay format requires the
simultaneous addition of labeled (conjugated analyte)
and unlabeled analyte (from the sample). Both
labeled and unlabeled analyte then compete
simultaneously for the binding site on the monoclonal
capture antibody on the plate. Like the sequential
competitive inhibition format, the colored signal is
inversely proportional to the concentration of unlabeled
target analyte in the sample.
Detection
of labeled analyte may be made by using a peroxidase
substrate such as TMB, which can be read on a
microtiter plate reader. With a standard curve (1 blank
and 7 standards) and 3 controls, a 96-well microtiter
plate format can test 21 samples in triplicate and 37
samples in duplicate. By using various components
in the assay diluents, ICT will work to eliminate as
many sample preparation steps as possible to make the
ELISA simple and easy to run. Assay development will
begin as soon as purified antigen and antibody are
available.
If
the target analyte and necessary antibodies are
available, assay development generally costs between
$30,000 - $100,000 and usually takes 4-8 months.
Proposals are often broken down into 4 phases, which
detail time and cost estimates. Payments are often
structured with a front fee of 30% of the estimated
total, and milestone payments disbursed thereafter,
which can be paid after each phase or monthly.
When
the assay has been developed, we normally supply
customers with reagents for 25 immunoassay kits. They
can be supplied as individually packaged kits or in bulk
packaging (for a detailed description of the reagents in
an ELISA kit, see What
Are the Typical Components in an ELISA?). When
stored at 2o-8o C, each kit may
have a shelf life of at least 6 months. If you
need more kits, ICT will manufacture the components as
you order them (this usually requires a 3-6 week
lead-time). Once developed, the cost for additional kits
typically ranges from $50 to $300 each (with a minimum
manufacturing charge of $2,000). This price will
be determined during development and depends on the
expense of the kit components, the type of packaging
required, and the volume ordered. If you will be
testing samples at different locations, we can ship the
assay kits directly to the other laboratories (also
see Kit
Manufacturing).
This
sample proposal is meant to answer basic questions, and
to act as a project guideline. Depending on your
specific project, the amount of antigen required may
vary, conjugations may be necessary, the antibody may
need to be purified, sample preparation steps may be
necessary, and the length of time for the project will
vary. In order to answer some of your
questions, or to prepare a specific quote for your
project, please review the Assay
Development Questionnaire, and then contact us.
All prices are in US dollars.
SAMPLE
PROPOSAL
Competitive Inhibition 96-Well Microtiter Plate ELISA
Development
Required materials and
reagents to begin assay development:
- Analyte.
- Antibodies.
- Analyte negative
samples.
- Analyte positive
samples.
Phase I - Reagent
Preparation and Initial Assay Titration…………$
Time: 6-8 weeks
- Selection of
compatible monoclonal antibodies and labeled analyte.
- Titration of capture
antibody and labeled analyte to working dilutions.
- Development and
optimization of ELISA plate coating procedures for
optimal antigen capture and competitive inhibition
of labeled antigen binding to the plate-bound
capture antibody.
Phase II - Assay
Optimization……………………………………………$
Time: 8-10 weeks
- Selection of proper
diluents for sample and conjugate signal generation.
- Development of a
functional assay protocol within the target
sensitivity range of the analyte.
- Construction of a
functional standard curve to mimic performance
characteristics of the sample matrix.
Phase III - Assay
Validation……………………………………………$
Time: 4-5 weeks
- Definition and
documentation of assay performance characteristics
essential for optimal assay utility (such as
sensitivity and precision).
- Documentation of diluent
performance parameters to assure proper matrix
composition (such as recovery and linearity).
- Fine-tuning of specific
assay components and incubation protocols to meet
final performance requirements.
Phase IV - Packaging of
Final Test Kit Product ………………………$
Time: 3-4 weeks
- Quality control
assessment of final kit components.
- Final assembly,
packaging, and delivery of components for 25
immunoassay kits.
Total Assay Development
Cost……………range of $30,000 - $100,000
Estimated Time: 21-27 weeks |